{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:36:54Z","timestamp":1772833014213,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200146"],"award-info":[{"award-number":["82200146"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014980","name":"Wannan Medical College","doi-asserted-by":"publisher","award":["YR202215"],"award-info":[{"award-number":["YR202215"]}],"id":[{"id":"10.13039\/501100014980","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.thromres.2025.109422","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T23:09:05Z","timestamp":1754435345000},"page":"109422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A real-world pharmacovigilance analysis of the FDA adverse event reporting system database for emicizumab"],"prefix":"10.1016","volume":"254","author":[{"given":"Tianyi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yizhi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2025.109422_bb0005","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2025.109422_bb0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/hae.13398","article-title":"Prevalence of and risk factors for cerebral microbleeds among adult patients with haemophilia A or B","volume":"24","author":"Husseinzadeh","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109422_bb0015","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jtha.2022.10.006","article-title":"Pre-existing anti-factor VIII immunity alters therapeutic platelet-targeted factor VIII engraftment following busulfan conditioning through cytotoxic CD8 T cells","volume":"21","author":"Jing","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109422_bb0020","author":"Genentech Inc."},{"key":"10.1016\/j.thromres.2025.109422_bb0030","doi-asserted-by":"crossref","first-page":"e57479","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2025.109422_bb0035","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109422_bb0045","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s40265-019-01200-2","article-title":"Emicizumab: a review in haemophilia A","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.thromres.2025.109422_bb0050","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4\u00a0weeks in people with haemophilia A@@@@ (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.thromres.2025.109422_bb0055","unstructured":"Hemlibra prescribing info. https:\/\/www.gene.com\/medical-professionals \/medicines\/hemlibra (accessed 24 Feb 2024)."},{"key":"10.1016\/j.thromres.2025.109422_bb0060","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1182\/blood-2018-99-118492","article-title":"Immunogenicity of Emicizumab in people with hemophilia a (PwHA): results from the HAVEN 1-4 studies","volume":"132","author":"Paz-Priel","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109422_bb0065","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1111\/jth.14957","article-title":"Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: new case with detailed laboratory evaluation","volume":"18","author":"Harkins Druzgal","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109422_bb0070","unstructured":"Emicizumab safety data. https:\/\/www.emicizumabinfo.com\/patient\/scientific-data\/safety-information.html (accessed 24 Feb 2024)."},{"key":"10.1016\/j.thromres.2025.109422_bb0075","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/14740338.2022.2016696","article-title":"A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system","volume":"21","author":"Shu","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.thromres.2025.109422_bb0080","article-title":"Acute kidney injury associated with Remdesivir: a comprehensive pharmacovigilance analysis of COVID-19 reports in FAERS","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.thromres.2025.109422_bb0085","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40780-016-0048-5","article-title":"Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese adverse drug event report database","volume":"2","author":"Abe","year":"2016","journal-title":"J. Pharm. Health Care Sci."},{"key":"10.1016\/j.thromres.2025.109422_bb0090","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","year":"2013","journal-title":"Drug Saf."},{"key":"10.1016\/j.thromres.2025.109422_bb0095","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40780-015-0035-2","article-title":"Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events","volume":"1","author":"Nakamura","year":"2015","journal-title":"J. Pharm. Health Care Sci."},{"key":"10.1016\/j.thromres.2025.109422_bb0100","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.thromres.2025.109422_bb0105","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.thromres.2025.109422_bb0110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.thromres.2025.109422_bb0115","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data Mining in Large Frequency Tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am. Stat."},{"key":"10.1016\/j.thromres.2025.109422_bb0120","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database","volume":"346","author":"Jiang","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.thromres.2025.109422_bb0125","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A real-world disproportionality analysis of Olaparib: data Mining of the Public Version of FDA adverse event reporting system","volume":"14","author":"Shu","year":"2022","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.thromres.2025.109422_bb0130","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s11096-022-01514-4","article-title":"Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database","volume":"45","author":"Wei","year":"2023","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.thromres.2025.109422_bb0135","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2025.109422_bb0140","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2025.109422_bb0145","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109422_bb0150","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.jtha.2024.02.009","article-title":"Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018\u20132022 US Food and Drug Administration Adverse Event Reporting System data","volume":"22","author":"Cho","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109422_bb0155","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109422_bb0160","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/jth.14556","article-title":"Emicizumab and thrombosis: the story so far","volume":"17","author":"Makris","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109422_bb0165","first-page":"478","article-title":"The role of recombinant activated factor VII in the haematological management of elective orthopaedic surgery in haemophilia A patients with inhibitors","volume":"15","author":"Castaman","year":"2017","journal-title":"Blood Transfus."},{"key":"10.1016\/j.thromres.2025.109422_bb0170","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14203","article-title":"In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents","author":"Hartmann","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109422_bb0175","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/jth.14491","article-title":"Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program","volume":"17","author":"Levy","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109422_bb0180","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2147\/TCRM.S205310","article-title":"Concomitant use of rFVIIa and emicizumab in people with hemophilia A with inhibitors: current perspectives and emerging clinical evidence","volume":"16","author":"Linari","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.thromres.2025.109422_bb0185","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood-2020-139568","article-title":"Real-world experience using emicizumab prophylaxis for hemophilia a: single-center experience","volume":"136","author":"Vagrecha","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109422_bb0190","first-page":"29","article-title":"Real-world safety of emicizumab: the first interim analysis of the European Haemophilia Safety Surveillance (EUHASS) database","volume":"136","author":"Shang","year":"2020","journal-title":"Blood"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825001720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825001720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:02:19Z","timestamp":1772805739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384825001720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":36,"alternative-id":["S0049384825001720"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109422","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A real-world pharmacovigilance analysis of the FDA adverse event reporting system database for emicizumab","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109422","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109422"}}